Story perspectives

GLP-1 Use Climbs 11%, Obesity Falls to 36%

7/9/2026

Summary

Gallup Reports Surge

Gallup surveyed 5,065 U.S. adults May 28-June 5 2026 and found 11% using GLP-1 drugs for weight loss.
GLP-1 use rose from 3% in 2024 to 11% in 2026, which Gallup links to the drop in obesity from 39.9% to 36.4%.
Sixty-eight percent of users take Wegovy or Zepbound and report severe nausea and taste changes.
An oral Wegovy pill received approval in late 2025.

Summary

Trump Caps GLP-1

President Donald Trump’s temporary Medicare program caps GLP-1 drugs at $50 a month for about 4 million new beneficiaries.
Private insurers are inconsistent, with many covering little or none of the $500-a-month price.
A JAMA secret-shopper study of 49 online pharmacies found four denials and a median one-day fulfillment.
Two prescriptions were issued within five minutes.
Twenty percent of sites approved orders using only an upper-body photo.

Summary

Gallup Finds Compounding

The FDA ordered a halt to non-branded compounding of GLP-1 drugs last year, yet Gallup found 19 % of users still rely on compounded versions.
Forty percent of compounded-drug users rate their medication “extremely effective,” versus 32 % of brand-name users, showing comparable perceived efficacy.
Thirty-five percent of compounded-drug users switched from a brand-name GLP-1, while only 10 % of brand-name users switched to compounded versions, indicating a net migration toward cheaper alternatives.

1 of 3

Gallup Reports Surge

Gallup surveyed 5,065 U.S. adults May 28-June 5 2026 and found 11% using GLP-1 drugs for weight loss.
GLP-1 use rose from 3% in 2024 to 11% in 2026, which Gallup links to the drop in obesity from 39.9% to 36.4%.
Sixty-eight percent of users take Wegovy or Zepbound and report severe nausea and taste changes.
An oral Wegovy pill received approval in late 2025.

1 / 3